CHICAGO, Jan. 4 /PRNewswire/ -- Endorex Corporation (Amex: DOR) announced
today that it has accelerated the release of the contractual lock-up period
relating to a $20 million private placement of Endorex common stock completed
in October 1997.  As of today, 100% of the shares from this placement are
available for trading and no longer subject to any further lock-up
restriction.  Under the previous provisions, the private placement investors
agreed not to sell the last remaining 25% of their shares (approximately 1.7
million shares) until February 5, 1999.   As a result of this action, the
total "public float" of Endorex common stock increased to approximately 7.3
million shares.
    "Eliminating the final lock-up period earlier than scheduled increases the
liquidity of our stock to our current investors and provides additional float
necessary to attract new investors," said Michael Rosen, president and chief
executive officer of Endorex.
    Endorex Corporation is a drug delivery and cancer products company
headquartered in Lake Forest, Ill.  Orasomal Technologies, Inc., Endorex's
oral delivery subsidiary, licensed technology from the Massachusetts Institute
of Technology (MIT) that is being developed to deliver vaccines, proteins and
peptides.  In 1998, Endorex formed two joint ventures with Elan Corporation,
plc (NYSE: ELN).   The first joint venture, Innovax, is developing oral
delivery systems for human and animal vaccines.  Endorex is focusing on two
innovative directions in cancer therapy: immunotherapy with ImmTher(R) and
natural cancer therapy with Perillyl alcohol (POH), a novel anticancer agent
based on monoterpenes.  Several Phase II clinical trials for Endorex's cancer
drugs were initiated during 1998.
    The statements made in this press release contain certain forward-looking
statements, within the meaning of Section 21E of the Securities Exchange Act
of 1934, as amended, that involve a number of known and unknown risks and
uncertainties.  Such statements are only predictions and actual events or
results in future periods may differ materially from what is currently
anticipated.  In addition to the matters described in this press release, risk
factors as described from time to time in Endorex's filing with the Securities
and Exchange Commission, including, but not limited to, its most recent
reports on Form 10-QSB and Form 10-KSB, may affect the results achieved by
Endorex.  The Company assumes no obligation to update the information in this
release.

Link to this page: